1. Medtech Insight

Regulators Compare US, Japan Approaches To Digital Health

 
• By Hannah Daniel

A discussion of Japanese and American digital health regulations at CRT2023 in Washington, DC, explored the similarities between the two countries and how we regulate software and connected devices.

• Source: Shutterstock

The digital health revolution is taking the world by storm, and Japan and America have similar ways of regulating the growing industry, Japanese officials explained at an FDA-Japan session during the Cardiovascular Research Technologies 2023 conference in Washington, DC, on 27 February.

Japan and America have long collaborated on medical device regulations. The US-Japan Medical Device Harmonization by Doing program was established in December 2003. The working group is a collaboration...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Digital Technologies

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By Ashley Yeo

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 
• By Natasha Barrow

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.